“Computational Analysis of FDA-Approved Drugs for Potential Repurposing in Alzheimer’s Disease: Targeting mTOR and NGFR Pathways”, Sci. Ess. J, vol. 42, no. 1, pp. 50–70, Jan. 2026, doi: 10.69523/sej.2026.42.17130.